

DIVISION OF RHEUMATOLOGY

Rheumatology is a developing sub-specialty both within the Department of Medicine and in Hong Kong. Currently, the team consists of one full-time academic staff, 2 honorary lecturers, 2 post-membership career trainees, one full-time technician and one research assistant.

Staff who have contributed to the achievements of the Division during the past decade include the following:

Current members

Physicians

Dr. R.W.S. Wong, *MBBS, FRCP(E), FRCP(G), FHKCP, FHKAM (Medicine)*
Consultant and Chief of Division

Dr. C.S. Lau, *MD (Hons), MRCP(UK), FHKCP, FHKAM (Medicine)*
Lecturer

Trainees

Dr. K.W. Lee, *MBBS, MRCP(UK)*
Medical Officer

Dr. C.C. Mok, *MBBS, MRCP(UK)*
Medical Officer

Past members

Dr. K.L. Wong, *MD, MRCP(UK), FHKCP, FHKAM (Medicine)*

Dr. K.H. Chan, *MBBS, FRCP(E), FHKCP, FHKAM (Medicine)*

CLINICAL SERVICE

The Division is responsible for the investigation and management of patients with various rheumatic diseases on both in- and out-patient basis. There is one General Rheumatology Clinic in Tang Chi Ngong Hospital and one in Sai Ying Poon Polyclinic Hospital. The average patient attendance at each of these 2 clinics is 70 per week. In addition, there are 2 Rheumatology Clinics (Dr. RWS Wong) and one Special Rheumatology Clinic (Dr. CS Lau) in Queen

Mary Hospital. An average of a further 70 patients are seen at these 3 clinics each week. An alternate week Combined Orthopaedic and Rheumatology Ankylosing Spondylitis Clinic with an average attendance of 30 patients is also in place at the Duchess of Kent Hospital in Sandy Bay. A wide spectrum of rheumatological disorders ranging from soft tissue rheumatism to various forms of arthropathies, connective tissue disorders and vasculitides are seen at these clinics. For arthritis patients requiring surgical intervention, there is close collaboration with the orthopaedic surgeons. Thus, patients from the Tang Chi Ngong Clinic can be referred directly to Dr FK Ip of the Pamela Youde Nethersole East Hospital and those from the Sai Ying Poon are seen by University Orthopaedic Surgery staff in the same clinic.

In-patient treatment is based both at the Queen Mary Hospital and the McLehose Medical Rehabilitation Centre (MLMRC) in Sandy Bay. The MLMRC has a good setup for the multi-disciplinary management of patients with chronic arthritis with facilities for physical therapy, occupational therapy and orthotic and prosthetic appliances. Help and advice from medical social workers, clinical psychologists and orthopaedic surgeons are also available.

As most rheumatic disorders are chronic and disabling, patient education is an essential part of their rehabilitation process. Public education is also needed to enhance the community's awareness of our patients' plights. Both are being accomplished through our Division's involvement in the various rheumatic disease patient self-help groups in Hong Kong. These include the Hong Kong Lupus Association, Hong Kong Rheumatoid Arthritis Association, Ankylosing Spondylitis Self Help Group and the Alliance for Patient's Mutual Help Organisation. There is also participation in public health exhibitions and lectures as well as contribution of published articles on related issues in the media.

There are also close links between the Division

and the Hong Kong Society for Rehabilitation and staff members are advisors of the Society's recently set up Community Rehabilitation Network and Vocational Re-training Services for Physically Disabled Persons.

EDUCATION

Undergraduate clinical teaching in Rheumatology takes the format of regular lectures (one in Immunology and 6 in Rheumatology), small group tutorials and seminars as well as teaching at bedside and specialist clinics. In addition, there are 2 Integrated Teaching Sessions each year on AIDS and Management of Rheumatoid Arthritis. We also supervise elective medical students, local and overseas, in Rheumatology. Besides teaching undergraduate medical students, the Division also takes part in the teaching of undergraduate dental students (2 lectures), BSc (Immunology) students (2 lectures and 2 tutorials) and nurses (2 lectures).

Postgraduate training in Rheumatology has changed much over the last few years. There is active participation in the Basic Physician and Rheumatology Specialist Training Programmes of the Hong Kong College of Physicians (HKCP). Dr. RWS Wong is the chairman while Drs. CS Lau and KH Chan (Honorary Lecturer) are members of the College's Subspecialty Advisory Committee in Rheumatology. A quarterly Inter-hospital Rheumatology Meeting was set up in 1992 and other postgraduate teaching activities have since been in place. These include a weekly Rheumatology Round, combined Rheumatology/Radiology Meeting, combined Rheumatology/Histopathology Meeting, Clinical Immunology Meeting and Journal Club. These meetings are attended by physicians, clinical immunologists and rheumatology trainees from Queen Mary Hospital as well as other district general hospitals and contribute to part of their training accreditation. Other postgraduate teaching commitments include small group tutorials and bedside teaching for local HKCP/Royal College of Physicians (UK) diploma examination candidates. The Division also contributes questions for the written paper in this examination. There are also 3 regular lectures for licentiate doctors.

Through the Division's involvement in the Hong Kong Society of Rheumatology, we have been able to extend postgraduate rheumatology training to a broader group of doctors, notably private general practitioners. Regular meetings have been organised and renowned local and overseas rheumatologists were invited to speak at these meetings.

RESEARCH

Due to understaffing of academic members of the Division, research in rheumatology was relatively scarce in the 1980's. There is, however, improvement in recent years with support from the Department and successes in bidding for competitive research grants. Basic research directions are being established. Collaborative links with other clinical and pathology departments of the University as well as many rheumatology centres overseas have also been set up. Most of the projects are yielding encouraging results and have been selected for presentations at various major regional and international rheumatology conferences. Further expansion is envisaged. Research in rheumatology, past and current, is summarised below:

Systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is an autoimmune disorder characterised by a profound disturbance of immune mechanisms. It typically affects female of reproductive age and may manifest with multi-organ involvement. Because of these, SLE has always stimulated interests from researchers of various disciplines.

Clinical features of SLE in Hong Kong have been studied. Thus, the annual incidence of this condition presenting to the Queen Mary Hospital and the Nethersole Hospital was estimated as 0.13%. The clinical pattern of this disease such as patients' initial presentation, course of illness, response to treatment and development of complications to treatment have been well documented. Particular emphasis was made on major organ complications of SLE. Prospective studies on the neurological manifestations, cardiac abnormalities and assessment using

advanced echocardiographic techniques, development of acute severe thrombocytopenia and clinical manifestations of patients who possessed the anti-phospholipid antibodies have been carried out. A study of the mechanism of thrombosis in patients with SLE and anti-phospholipid antibody syndrome was completed recently and evidence of vascular damage, abnormal plasma fibrinolysis, activated platelets and white cells were found in these patients. Correction of these abnormalities may improve prognosis.

Since SLE predominately affects young females, the outcome of pregnancy in these patients has been a major concern. A prospective study was therefore carried out and it showed low maternal and fetal morbidity and mortality rates can be achieved with close maternal monitoring and good neonatal supportive care.

Recent studies have concentrated more on the aetiology and pathophysiology of SLE. Immunogenetics of this condition were studied and HLA B5 was found to be associated with the presence of other autoimmune diseases while HLA DR2 was associated with the presence of anti-Ro antibody. Acetylator status and the development of SLE was studied but no significant association was found. An infective agent(s) has been suggested to play a role in the aetiology of SLE but such an agent(s) has remained elusive. Cytomegalovirus and Epstein Barr virus were examined but neither was found to be associated with the onset or relapse of SLE. On the other hand, susceptibility to this condition may be linked to a deficiency state in mannose binding protein, a recently characterised lectin which is capable of activating the complement pathway. Results from this study have generated many follow-up projects which are currently underway. Other possible aetiological factors such as defective apoptosis are also under investigation.

Whatever the cause of SLE, there are widespread changes in the patient's immune system. Increased T-lymphocyte activity was suggested by the demonstration of increased interleukin-2 receptor expression on peripheral lymphocytes of these patients. The level of soluble interleukin-2 receptor in serum correlated with clinical disease

activity. The role of B-cells in SLE has also been studied. Results from a cross-sectional study on CD5+ve and CD5-ve B-lymphocytes suggested excessive production of pathogenic anti-dsDNA antibodies by CD5-ve B-cells may be due to diminished CD5+ve B-cell activity.

The pathogenic mechanism of complications of SLE is due mainly to auto-antibody production, immune complex formation, complement activation and consequent vasculitis. Measurement of complement degradation products and factor VIII von Willebrand factor antigen (vWF), an endothelial product, was assessed as markers of disease activity. Both showed significant correlation with fluctuation of disease activity but plasma vWF measurement appeared to be more clinically applicable.

Other ongoing SLE projects include a multi-centre study on lupus nephritis therapy and prevention and treatment of steroid induced osteoporosis.

Raynaud's phenomenon and systemic sclerosis

Raynaud's phenomenon (RP) may be primary or secondary, mostly to connective tissue disorders. Patients characteristically complain of pain and blanching of fingers following cold exposure and emotional stress. Most of the related work aimed (1) to determine the pathophysiological role of the haemostatic systems in primary and secondary RP and (2) to explore the potential for treatment with manipulation of the arachidonic acid (AA) pathway in favour of anti-thrombotic and vasodilatory effects. Our previous studies clearly demonstrated the key aetiological role of abnormal haemostasis in RP, particularly those with the secondary form such as systemic sclerosis. These patients had endothelial dysfunction in addition to platelet and white cell activation which occurred in all RP patients. It was likely that most of these abnormalities were a consequence rather than a cause of RP. Nevertheless, such changes might worsen the condition by further decreasing digital blood flow. Correction of these changes can be achieved through manipulation of the AA pathway. The effects of direct intravenous infusion of prostacyclin, oral and intravenous administration

of prostacyclin analogues and thromboxane A₂ receptor blockade were investigated. All were shown to have potential therapeutic value.

Rheumatoid arthritis

Rheumatoid arthritis (RA) is a chronic disabling inflammatory polyarthritis. Its incidence in Hong Kong was estimated as 0.12% in an earlier study. Susceptibility to this condition was shown to be linked to HLA DR allelic third hypervariable region sequences.

Once RA has declared itself, it may run a progressive relapsing and remitting course and a careful management plan is required to prevent deterioration and complications. The use of anti-rheumatic drugs remains the main stay of treatment for these patients. Dietary modulation of essential fatty acid intake has been studied and the use of eicosapentaenoic acid was shown to have anti-inflammatory effects. Newer anti-rheumatic drugs such as bucillamine and analogues for RA are also being studied in collaboration with the Department of Chemistry. Thunder God Vine (triptolide), a Chinese herbal medicine, is widely used for RA and SLE in Mainland China and Hong Kong. The immunological effects of this agent have not been fully evaluated and a collaborative project with the Department of Chemistry has recently been set up to have these delineated. Preliminary results suggest this drug may have cytotoxicity effects.

Ankylosing spondylitis

There have been few studies in ankylosing spondylitis (AS). Current on-going studies include (1) HLA B27 tissue antigen sub-typing and (2) the clinical usefulness of facet joint depo-steroid injection in patients with acute back symptoms.

Others

The Division is involved (Dr. CS Lau is Committee Member) in a recently set up World Health Organisation Study on Low Back Pain. This study aims to evaluate and compare different forms of clinical psychological and socio-economic assessments of patients with chronic low back pain.

FUTURE DIRECTIONS

There is an urgent need to expand Rheumatology both within the Department and in Hong Kong. Most rheumatic disorders are chronic and disabling. Some, such as SLE and the vasculitides, may be life-threatening. Rheumatic complaints account for a large proportion of the general practitioner's consultation. Well-structured undergraduate and postgraduate teaching programmes are therefore needed to prepare our students and colleagues to deal with patients with rheumatic disorders. Improvement in the management of our patients will only come about with better understanding of these conditions, and this could only be accomplished by basic and clinical research. Our Division, with support from the Department, will continue to work hard to fulfil the above objectives and to lead in the development of Rheumatology in Hong Kong and the Region. Some ground work has been laid but much more needs to be done. This is especially so in research which requires much dedication. Work on SLE will continue to expand. However, the other major rheumatic disorders such as RA and AS have, in general, been relatively neglected. The current academic staffing level needs to be revised to cater for further expansion. Obviously, patients' eventual outcome is our ultimate concern and improvement in the provision of patient care has to continue. A Centre for Rheumatic Disorders with full facilities for patient counselling and education, treatment of in- and out-patient acute and chronic rheumatic complaints as well as basic and clinical research should not be something that we dream of but something that we will continue to strive for.

PUBLICATIONS (from 1985)

Systemic lupus erythematosus

Yeung CK, KL Wong, Wong RWS, Chan MK, Ng WL. Unusual transformations of renal involvement in systemic lupus erythematosus. *Aust NZ J Med* 1985; 15: 69-71.

*Chan KH, Wong WS, Wong KL. Lupus anticoagulant among Chinese patients in Hong Kong. *J Hong Kong Med Assoc* 1985; 37: 185-186.

Yeung CK, Ng WL, Wong RWS, Wong KL, Chan MK. Acute deterioration in renal function in systemic lupus erythematosus. *Q J Med* 1985; 56: 393-402.

†Asherson RA, Chan JKH, Harris EN. Anticardiolipin antibody recurrent thrombosis and warfarin withdrawal. *Ann Rheum Dis* 1985; 44: 823-825.

†Harris EN, Gharavi AE, Ticani A, Chan JKH. Affinity-purified anticardiolipin and anti-DNA antibodies. *J Clin Lab Immunol* 1985; 17, 155-162.

†Harris EN, Gharavi AE, Loizou S, Derue G, Chan JKH, Patel BM. Crossreactivity of anti-phospholipid antibodies. *J Clin Lab Immunol* 1985; 16: 1-6.

Yeung CK, Wong KL, Wong RWS, Chan KH. β_2 -microglobulin and systemic lupus erythematosus. *J Rheumatol* 1986; 13: 1053-1058.

Wong KL, Tai YT, Loke SL, Woo EKW, Wong WS, Chan MK, Ma J. Disseminated zygomycosis masquerading as cerebral lupus erythematosus. *Am J Pathol* 1986; 86: 546-549.

†Mackworth-Young CG, Chan JKH, Harris EN. Complement fixation by anti-DNA antibodies in systemic lupus erythematosus: measurement by radioimmunoassay and relationship with disease activity. *Ann Rheum Dis* 1986; 45: 314-318.

†Mackworth-Young CG, Chan JKH, Harris EN. High incidence of anticardiolipin antibodies in relatives of patients with SLE. *J Rheum* 1987; 14:4, 723-726.

Wong RWS, Chan JKH, Wong KL. Lupus anticoagulant - A double misnomer. *Asian Pac J Allergy Immunol* 1987; 5: 161-165.

Woo J, Wong RWS, Wang SWS. The prevalence and incidence of systemic lupus erythematosus and rheumatoid arthritis among the Chinese population in Hong Kong. *ASEAN J Clin Sci* 1987; 7: 77-81.

Kwong YL, Wong KL, Kung ITM, Chan PCK, Lam WK. Concomitant alveolar haemorrhage and cytomegalovirus infection in a patient with systemic lupus erythematosus. *Post Med J* 1988; 64: 56-59.

Hawkins BR, Wong KL, Wong RWS, Chan KH, Dunckley H, Seyeantson SW. Strong association between the major histocompatibility complex and systemic lupus erythematosus in Southern Chinese. *J Rheumatol* 1987; 14: 1128-1131.

Liu HW, Wong KL, Lin CK, Wong WS, Tse PWT, Chan GTC. The reappraisal of dilute tissue thromboplastin inhibition test in the diagnosis of lupus anticoagulant. *Br J Haematol* 1989; 72: 229-234.

Chan PCK, Wong WS, Wong KL, Cheng IKP, Chan MK. Lupus nephritis patients on maintenance dialysis in Hong Kong. *Int J Artificial Organs* 1989; 12: 741-786.

Leung WH, Wong KL, Lau CP, Cheng CH, Wong CK. Cardiac abnormalities in systemic lupus erythematosus - a prospective M-mode, cross-sectional and pulsed Doppler echocardiographic study. *Int J Cardiol* 1990; 27: 367-375.

Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT. Doppler echocardiographic evaluation of left ventricular diastolic function in patients with systemic lupus erythematosus. *Am Heart J* 1990; 120: 82-87.

Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT. A Doppler-echo evaluation of left ventricular diastolic function in patients with mixed connective tissue disease. *Cardiology* 1990; 77: 93-100.

Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Tai YT. Echocardiographic identification of mitral valvular abnormalities in patients with mixed connective tissue disease. *J Rheumatol* 1990; 17: 485-488.

Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, Liu HW. Association between antiphospholipid antibodies and cardiac abnormalities in patients with systemic lupus erythematosus. *Am J Med* 1990; 89: 411-419.

Kumana CR, Chan MMY, Wong KL, Wong RWS, Kou M, Lauder IJ. Lack of association between slow acetylator status and spontaneous lupus erythematosus. *Clin Pharmacol Ther* 1990; 48:208-213.

Wong KL, Woo EKW, Yu YL, Wong RWS. Neurological manifestation of systemic lupus

erythematosus: a prospective study. *Q J Med* 1991; 81: 857-870.

Wong KL, Wong RWS, Hawkins BR. Immunogenetics in Chinese patients with systemic lupus erythematosus. *Scand J Rheumatol* 1991; 20: 110-114.

Wong KL, Chan FY, Lee CP. Outcome of pregnancy in patients with systemic lupus erythematosus: a prospective study. *Arch Int Med* 1991; 151: 269-273.

*Wong RWS. Drug treatment of systemic lupus erythematosus, Part II: Commentary from South East Asia. *Med Prog* 1991; 18: 46-47.

Wong KL, Wong RPO. Limitation of serum soluble interleukin-2 receptor in defining the activity in patients with systemic lupus erythematosus. *Ann Rheum Dis* 1991; 50: 706-709.

Wong KL, Liu HW, Ho K, Chan K, Wong R. Anticardiolipin antibodies and lupus anticoagulant in Chinese patients with systemic lupus erythematosus. *J Rheumatol* 1991; 18: 1187-1192.

Wong KL. Danazol in treatment of lupus thrombocytopenia. *Asian Pac J Allergy Immunol* 1991; 9: 125-129.

Wong KL. Systemic lupus erythematosus in Hong Kong [MD thesis]. Hong Kong: The University of Hong Kong, 1981.

Wong KL. Pattern of systemic lupus erythematosus in Hong Kong Chinese: a cohort study. *Scand J Rheumatol* 1992; 21: 289-296.

Leung WH, Wong KL, Lau CP, Wong CK. Purulent pericarditis and acute cardiac tamponade caused by nocardia asteroides in mixed connective tissue disease. *J Rheumatol* 1991; 17: 1237-1239.

Chen RYL, Wong KL, Lawton JWM, Ho FCS. Anti-nuclear antibody detection using streptavidin-biotin-peroxidase complex on Hep-2 cell substrate. *Asian Pac J Allergy Immunol* 1992; 10: 19-24.

Lau CS. Antiphospholipid syndrome. *Vascular Med Rev* 1994; 5: 33-45.

Jones BM, Lau CS, Wong RWS. CD5-positive and CD5-negative plaque-forming cells against

poly-l-lysine-treated sheep erythrocytes in patients with systemic lupus erythematosus. *Autoimmunity* 1994; 18: 189-194.

Mok CC, Lau CS, Poon SP. Primary nocardial meningitis in systemic lupus erythematosus. *Br J Rheumatol* 1995; 34: 178-181.

Mok CC, Lau CS. Transverse myelitis and anti-phospholipid antibodies in mixed connective tissue disorders. *Clin Neurol Neurosurg* (in press).

Raynaud's phenomenon and systemic sclerosis

‡Lau CS, M McLaren M, Saniabadi A, Scott N and Belch JFF. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis - a preliminary study. *Clin Exp J Rheumatol* 1991; 9: 271-273.

‡Lau CS and Belch JFF. Raynaud's phenomenon - a vasospastic disorder. *Curr Pract Surg* 1991; 3: 170-175.

‡Lau CS, M McLaren M and Belch JFF. Factor VIII von Willebrand Factor antigen levels correlate with symptom severity in patients with Raynaud's phenomenon. *Br J Rheumatol* 1991; 30: 433-436.

‡Lau CS, Khan F, M McLaren M, Bancroft A, Walker M and Belch JFF. The effects of thromboxane receptor blockade on platelet aggregation and digital skin blood flow in patients with secondary Raynaud's syndrome. *Rheumatol Int - Clin Exp Invest* 1991; 11: 163-168.

‡Belch JFF, Lau CS, Forbes CD. Iloprost and risk of thrombo-embolism. *Am J Med* 1991; 91: 666-667.

‡Lau CS, O'Dowd A and Belch JFF. White cell activation in the Raynaud's phenomenon of systemic sclerosis and vibration induced white finger syndrome. *Ann Rheum Dis* 1992; 51: 249-252.

‡Lau CS, Bridges A, Muir A, Scott N, Bancroft A, Belch JFF. Further evidence of white cell activation in patients with Raynaud's phenomenon. *Br J Rheumatol* 1992; 31: 375-380.

‡Saniabadi AR, Fisher TC, Lau CS, Bridges A, Taylor J, Belch JFJ, Forbes CD. Dipyridamole increases human red cell deformability. *Clin Pharmacol* 1992; 42: 651-654.

‡Lau CS. Haemostatic abnormalities in Raynaud's phenomenon and the potential for treatment with manipulation of the arachidonic acid pathway [MD thesis]. Dundee, Scotland: University of Dundee, 1992.

†Lau CS, Belch JFJ, Madhok R, Cappell H, Herrick A, Jayson M, Thompson JM. A randomised double-blind group comparative placebo controlled study to assess the efficacy and tolerance of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's syndrome secondary to systemic sclerosis. *Clin Exp J Rheumatol* 1993; 11: 35-40.

†Lau CS, M McLaren M, Walker M, Belch JFJ. Increased whole blood platelet aggregation in patients with Raynaud's phenomenon with or without systemic sclerosis. *Scand J Rheumatol* 1993; 22: 97-101.

†Lau CS, McLaren M, Walker M, Belch JFJ. Baseline plasma fibrinolysis and its correlation with clinical manifestations in patients with Raynaud's phenomenon. *Ann Rheum Dis* 1993; 52: 443-448.

†Belch JFJ, M McLaren M, Lau CS, Saniabadi AR, Bancroft A, McEwen J, Thompson JM. Cicaprost, an orally active prostacyclin analogue: its effects on platelet aggregation and skin blood flow in normal volunteers. *Br J Clin Pharmacol* 1993; 35: 643-647.

†Lau CS, Khan F, McCallum P, Belch JFJ. Digital blood flow response to body warming, cooling and rewarming in patients with Raynaud's phenomenon. *Angiol* 1995; 46: 1-10.

†Belch JFJ, Capell HA, Cook ED, Kirby JDT, Lau CS, Madhok R, Murphy E, Steinberg M. Oral iloprost as a treatment for Raynaud's syndrome. A double-blind multi-centre placebo controlled study. *Ann Rheum Dis* (in press).

Rheumatoid arthritis

Woo J, Wong RWS, Wang SWS, Woo P. Patterns of rheumatoid arthritis and systemic lupus erythematosus in Hong Kong. *Ann Rheum Dis* 1987; 46: 644-646.

*Wong RWS, Wong B, Tai YT. Penicillamine induced polymyositis in rheumatoid arthritis. *ASEAN J Clin Sci* 1988; 8: 85-87.

Wong RWS. Biopsy proven lupus nephritis in a patient with erosive rheumatoid arthritis. *ASEAN J Clin Sci* 1990; 10: 97-104.

‡McLaren M, Lau CS, Forbes CD and Belch JFJ. Seasonal variation in fibrinolysis in patients with rheumatoid arthritis. *Fibrinolysis* 1990; 4: 116-117.

‡Lau CS, Gallacher C, Ross P and Belch JFJ. Rheumatoid arthritis - snake oil or fish oil?. *Br J Rheumatol* 1991; 30: 72-73.

Jones BM, Cheng IKP, Wong RWS. Aberrant T-regulation in rheumatoid arthritis and IgA nephropathy affects CD5+ve and CD5-ve B lymphocytes equally. *Clin Exp Immunol* 1991; 86: 212-218.

Seglias J, Li EKM, Cohen MG, Wong RWS, Potter PK, So AK. Susceptibility to rheumatoid arthritis is linked to HLA-DR allelic third hypervariable region sequences in Southern Chinese. *Arthritis Rheum* 1992; 35: 163-167.

Jones BM, Cheng IKP, Wong RWS, Kung AWC. CD5+ve and CD5-ve rheumatoid factor-secreting cells in IgA nephropathy, rheumatoid arthritis and Grave's disease. *Scand J Immunol* 1993; 38: 575-580.

M Ip Wong MP, Wong KL. Rheumatoid nodule in the trachea. *Chest* 1993; 103: 301-303.

†Lau CS, Belch JFJ. The *in vitro* free radical scavenging effects of tenidap, a dual cyclo-oxygenase and 5-lipoxygenase inhibitor - a preliminary study. *Mediators of Inflamm* 1993, 1: 141-143.

†Lau CS, Morley KD, Belch JFJ. Effects of Maxepa fish oil supplementation on non-steroidal anti-inflammatory drug requirement in patients with mild rheumatoid arthritis - a double blind placebo controlled study. *Br J Rheumatol* 1993; 52: 443-448.

†Lau CS, McLaren M, Hanslip J, Kerr M, Belch JFF. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis. *Ann Rheum Dis* 1993; 52: 643-649.

†Lau CS, Saniabadi AR, Belch JFF. Reduced red blood cell deformability in patients with rheumatoid vasculitis: Improvement after in vitro treatment with dipyridamole. *Arthritis Rheum* 1995; 38: 248-253.

†Lau CS, McLaren M, Belch JFF. Effects of fish oil on plasma fibrinolysis in patients with mild rheumatoid arthritis. *Clin Exp J Rheumatol* 1995; 13: 87-90.

Mok CC, Kwong YL, Lau CS. Secondary acute myeloid leukaemia with 7q-complicating azathioprine treatment for rheumatoid arthritis. *Ann Rheum Dis* (in press).

Miscellaneous Rheumatology

Wong RWS. Leprosy masquerading as nodular vasculitis. *Br J Rheumatol* 1987; 26: 398.

Leung WH, Wong KL, Lau CP, Wong CK, Cheng CH, So KF. Myocardial involvement in Churg-Strauss Syndrome - the role of endomyocardial biopsy. *J Rheumatol* 1989; 1: 828-831.

Tai YT, Fong PC, Ng WF, Fu KH, Chow WH, Lau CP, Wong WS. Diffuse aortitis complicating Behcet's disease leading to severe aortic regurgitation. *Cardiol* 1991; 79: 156-160.

*Wong RWS. Intralesional corticosteroids Part II: Their role in clinical rheumatology. Commentary from South-east Asia. *Med Prog* 1991; 18: 43-44.

Lau CS. Diseases of joints and bones. In: Forbes CD and Jackson WF, eds. *A colour atlas and text of clinical medicine*. Ayelsbury, England: Wolfe Publishing, 1993: 121-160.

Chan TM, Cheng IKP, Wong KL, Chan KW. Resolution of membrano-proliferative glomerulonephritis complicating angiofollicular lymph node hyperplasia (Castleman's disease). *Nephron* 1993; 65: 628-632.

Wong BC, Wong KL, Ip MS, Wang EP, Chan KW, Chan LC. Sjogren's syndrome with amyloid

A presenting as multiple pulmonary nodules. *J Rheumatol* 1994; 21: 165-167.

‡Keys J, Beardon P, Lau CS, Lang CC, McDevitt DG. General practitioner use of non-steroidal anti-inflammatory drugs in Tayside and Fife regions. *J Roy Soc Med* 1992; 85: 442-445.

Kung A, Lau CS, Wu PC. Graves' ophthalmopathy and relapsing polychondritis. *Clin Exp J Rheumatol* (in press).

Chan WM, Ip M, Lau CS, Wang E, Peh WCG. Anti-Jo-1 syndrome presenting as cryptogenic organizing pneumonia. *Resp Med* (in press).

Clinical immunology

†Gibson J, Wong KL, Basten A. Maternal autoimmune disease influences self-tolerance in offspring. *Adv Exp Med Biol* 1985; 186: 495-502.

†Basten A, Gibson J, Loblay RH, Wong KL, Fazeka de St Groth B. The role of memory suppressor T cells in self-tolerance: induction in utero and in athymic mice. *Adv Exp Med Biol* 1985; 186: 511-520.

Wong RWS, So SY, Ha SY, Chow L, Young R, Todd D. AIDS in a Hong Kong Chinese. *Asian Pac J Allergy Immunol* 1986; 4: 37-39.

Lok ASF, Liang RHS, Chiu EKW, Wong KL, Chan TK, Todd D. Reactivation of hepatitis B virus in patients receiving cytotoxic therapy. Report of a prospective study. *Gastroenterol* 1991; 100: 182-188.

Kung AWC, Lai CL, Wong KL, Tam CF. Thyroid functions in patients treated with interleukin-2 and lymphokine-activated killer cells. *Q J Med* 1992; 82: 33-42.

Chan TM, Cheng IKP, Wong KL, Chan KW, Lai CL. Crescentic IgA glomerulonephritis following IL-2 therapy for hepatocellular carcinoma of liver. *Am J Nephrol* 1991; 11: 493-496.

Jones BM, Lau YL, Wong KL. B cell and T-regulatory cell dysfunction in six Chinese children with hypogammaglobulinaemia. *Eur J Paediatr* 1993; 152: 409-413.

Other articles

‡Lang CC, Lau CS, Belch JFF and Struthers AD.

Effect of atrial natriuretic factor on platelet function in whole blood ex-vivo in man. *Eur J Clin Pharmacol* 1990; 39: 589-591.

‡Belch JJF, Lau CS, Shaw W and McLaren M. Oxygen free radical generation following angioplasty for peripheral vascular disease. In: Palombo D, Brustia P, Domenico Palombo, Valle D'Aosta, eds. *La Chirurgia Vascolare nella Comunità Economica Europea*. 1991: 127-128.

‡Lau CS, Scott N, Shaw W and Belch JJF. Increased activity of oxygen free radicals during reperfusion in patients with peripheral arterial disease undergoing percutaneous peripheral artery balloon angioplasty. *Int Angiol* 1991; 10: 244-246.

† *Publications produced by staff whilst attached to or visiting other centres*

‡ *Publications produced by staff while employed at other centres before joining the Department*

* *Publications in non-indexed journals*

**C.S. Lau and
Raymond W.S. Wong**